ImaginAb, a UCLA spinout that has now raised approximately $4m in total, will continue development of the imaging agent it is developing for T-cell tumours.
ImaginAb, a US-based diagnostic imaging technology developer spun out from University of California, Los Angeles (UCLA), completed an $8m funding round on Monday featuring research institute Parker Institute for Cancer Immunotherapy.
The round was led by hedge fund sponsor Adage Capital Management with backing from venture capital firms Cycad Group and Nextech Invest, Novartis Venture Fund (NVF), the corporate venturing unit formed by pharmaceutical firm Novartis and Jim Pallotta.
ImaginAb, founded in 2007, has developed technology that reengineers antibodies into…
